We showed that RRM1 and NME1 were significantly upregulated in both pyrimidine and purine synthesis pathways in glioblastoma, elevated more than twofold compared to near-normal brain, suggesting that these enzymes might offer therapeutic targets for the treatment of glioblastoma. The gene discussed is NME1; the disease is glioblastoma.